| Price | 5.23 |
| Price Change Today | -$0.39 (-6.94%) |
| P&P rating | ![]() |
| Zacks Rank | N/A - N/A |
| Open Price | $5.60 |
| Previous Close | $5.62 |
| Daily Range | $4.97 - $5.62 |
| 52-Week Range | $2.66 - $24.30 |
| Volume | 103,002 |
| Telik, Inc. is a biopharmaceutical company focused on the discovery and development of small-molecule biopharmaceuticals for itself and its partners. Three lead programs address large markets in oncology and diabetes. They include TLK286 for chemotherapy-resistant solid tumors, TLK199 for chemotherapy-induced neutropenia, and TLK17411 for Type II diabetes. The company intends to maximize the commercial potential of each of its development programs through corporate partnerships that promote accelerated commercialization of its products. | |




Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment